| [1] |
Qin S, Ren Z, Feng Y, et al. Atezolizumab plus bevacizumab versus sorafenib in the Chinese subpopulation with unresectable hepatocellular carcinoma: phase 3 randomized, open-label IMbrave150 study[J]. Liver Cancer, 2021, 10(4): 296-308.
|
| [2] |
Vogel A, Rimassa L, Sun HC, et al. Comparative efficacy of atezolizumab plus bevacizumab and other treatment options for patients with unresectable hepatocellular carcinoma: A network Meta-analysis[J]. Liver Cancer, 2021, 10(3): 240-248.
|
| [3] |
Kudo M, Motomura K, Wada Y, et al. Avelumab in combination with axitinib as first-line treatment in patients with advanced hepatocellular carcinoma: results from the phase 1b VEGF liver 100 trial[J]. Liver Cancer, 2021, 10(3): 249-259.
|
| [4] |
Chiang CL, Chan SK, Lee SF, et al. Cost-effectiveness of pembrolizumab as a second-line therapy for hepatocellular carcinoma[J]. JAMA Netw Open, 2021, 4(1): e2033761.
|
| [5] |
Kelley RK, Sangro B, Harris W, et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase Ⅰ/Ⅱ study[J]. J Clin Oncol, 2021, 39(27): 2991-3001.
|
| [6] |
Ding X, Sun W, Li W, et al. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study[J]. Cancer, 2021,127(20): 3782-3793.
|
| [7] |
Chen S, Wu Z, Shi F, et al. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: A retrospective study[J]. J Cancer Res Clin Oncol, 2021: s00432-021-03767-4.
|
| [8] |
Tabrizian P, Jibara G, Shrager B, et al. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis[J]. Ann Surg, 2015, 261(5): 947-955.
|
| [9] |
Versluis JM, Long GV, Blank CU. Learning from clinical trials of neoadjuvant checkpoint blockade[J]. Nat Med, 2020, 26(4): 475-484.
|
| [10] |
Marron TU, Fiel MI, Hamon P, et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: A single-arm, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(3): 219-229.
|
| [11] |
Kaseb AO, Hasanov E, Cao HST, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: A randomised, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7(3): 208-218.
|